ProteaPex Therapeutics’ patented, platform technology of locally-delivered therapeutics
ProteaPex Therapeutics’ technology is a novel method of Matrix Metalloprotease inhibition
ProteaPex Therapeutics’ innovative disease modifying therapeutics
Chief Science Officer, Marina D'Angelo PhD., talks about Osteoarthritis Research
February 13, 2024
ProteaPex Pitches Our Osteoarthritis Products
Dr. D’Angelo, our CSO, will pitch our osteoarthritis products at the Philly Life Science Tech Transfer Showcase, hosted by BioStrategy Partners and BioLabs Philadelphia (https://www.biostrategypartners.org/event-5552994). In addition, ProteaPex Therapeutics will present posters on our dietary supplement product development and our platform technology of the Extracellular Matrix Protection Factors and their therapeutic value in several diseases.
June 16, 2019
CSO Discusses ECPF-1, a Novel Osteoarthritis Therapeutic
Dr. Marina D’Angelo, CSO, discussed development of ECPF-1, the novel, injectable therapeutic that slows the progression of osteoarthritis.
March 23, 2024
ECPF-2 poster presented at American Association for Anatomy in Toronto, Canada
Elastin is the main extracellular matrix protein that gives the alveolar walls their elastic properties. Its production and degradation are further regulated by transforming growth factor beta (TGF-b) and its storage molecule, latent transforming growth factor beta binding protein (LTBP-1). ECPF-2 treatment increased elastin and LTBP-1 incorporation into the extracellular matrix. These data suggest that ECPF-2 can decrease the symptoms of extracellular matrix degradation associated with pulmonary fibrosis in COPD.
Extracellular Matrix Protection Factor (ECPF-1) is a novel, safe and effective intra-joint injection that reduces the pain and damage caused by osteoarthritis.
Extracellular Matrix Protection Factor-2 (ECPF-2), is a safe, non-antibiotic oral healthcare treatment that slows the damage associated with periodontal disease.
Extracellular Matrix Protection Factor-3 (ECPF-3) can block the cellular players that cause narrowing of airways in Chronic Pulmonary Obstructive Diesase (COPD) and asthma.
ProteaPex Therapeutics holds broad-based patents detailing a disruptive technology that can accommodate a platform of products to address many diseases.
Extracellular Matrix Protection Factor (ECPF) is a novel, safe and effective platform of locally delivered therapeutics. The ECPFs target diseases where abnormal breakdown of the organ tissue is a sign of pathology. The patented mechanism of action is unlike any other competitors currently in development.
ProteaPex Therapeutics, LLC holds a broad-based patent application detailing a disruptive technology that can accommodate a platform of products to address many diseases.
Chief Executive Officer
Jeff Boily is a serial entrepreneur and investor with over 30 years of global life sciences experience. Jeff's emerging company and fund raising experience includes start-ups, growth stage and turnaround in pharmaceuticals, biotechnology, drug delivery, medical devices, and clinical informatics.
Chief Science Officer
Marina D’Angelo, PhD has over 25 years of experience in cell differentiation and cartilage biology. The major emphasis of her research endeavors has been chondrocyte biology. Over the last 20 years she has studied the role of growth factors and enzymes in normal chondrocyte differentiation and the disease pathway, osteoarthritis.
Use this form to contact us about Partnering, Investment or for more Info...